RhumbLine Advisers’s Rapport Therapeutics RAPP Stock Holding History

RhumbLine Advisers’s Portfolio RAPP Stock Details RAPP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.55M	Buy	37,198 +2,665	+8%	+$97.9K	﹤0.01%	2086
2026 Q1	$1.08M	Buy	34,533 +3,807	+12%	+$107K	﹤0.01%	2161
2025 Q4	$932K	Buy	30,726 +6,440	+27%	+$178K	﹤0.01%	2269
2025 Q3	$721K	Sell	24,286 -663	-3%	-$11.8K	﹤0.01%	2446
2025 Q2	$284K	Buy	24,949 +10,591	+74%	+$112K	﹤0.01%	3020
2025 Q1	$144K	Buy	14,358 +4,109	+40%	+$53.3K	﹤0.01%	3273
2024 Q4	$182K	Sell	10,249 -5,594	-35%	-$124K	﹤0.01%	3242
2024 Q3	$324K	Buy	+15,843	New	+$340K	﹤0.01%	2978

Other funds holding RAPP

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TGV

TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RhumbLine Advisers's RAPP Position: Q2 2026 in Review

RhumbLine Advisers increased its Rapport Therapeutics (RAPP) stake by 7.7% in Q2 2026, buying an estimated $97.9K and bringing the position to 37,198 shares worth $1.55M. The position accounts for ﹤0.01% of the portfolio, ranked #2086.

RhumbLine Advisers first reported a position in RAPP in Q3 2024 and has held it in 8 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

RhumbLine Advisers held 37,198 shares of Rapport Therapeutics worth $1.55M as of Q2 2026.
RhumbLine Advisers bought 2,665 Rapport Therapeutics shares in Q2 2026, an estimated $97.9K.
Rapport Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2086 holding.
RhumbLine Advisers first reported a position in Rapport Therapeutics in Q3 2024 and has held it in 8 quarters since.
161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.